However, consistent with literature [5, 8, 10, 11, 46–49], we observed that BC patients with germline CHEK2 c.1100delC or a somatic TP53 mutation have an unfavorable clinical outcome compared to wild-type patients. This evidence concerns the gene CHEK2 and breast cancer.